BridgeMD
LANDI-POAF study
EU CTIS ID: 2024-518950-17-00
What this study is testing
Prevention of postoperative atrial fibrillation using landiolol hydrochloride in patients undergoing elective on-pump cardiac surgery
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Male or female patients ≥ 18 years old
- Written informed consent from patient
- Patients are in sinus rhythm
- Oral Betablocker in the patients long-term medication
- One of the following cardiac surgical procedures which is planned on cardiopulmonary bypass (CPB): a. Single valve surgery b. Single or multiple CABG procedures c. Single valve surgery in combination with one or multiple coronary artery bypass grafts (CABGs) d. Multiple valve surgery in combination with or without CABG e. Single or multiple valve surgery in combination with ascending aorta procedure with or without additional CABG f. Re-surgery of aortic valve, mitral valve, aortic arch or ascending aorta with or without CABG
- Cardiac surgery is performed electively
You likely can't join if
- Bodyweight > 101kg and/or BMI ≥ 40
- Requiring inotropic, vasopressor or requiring ventilatory support at time of screening
- Circulatory shock requiring mechanical circulatory support before initiation of study medication
- Distributive shock (cardiac index>2.2 L/min with norepinephrine dose > 0.3 µg/kg/min to reach mean arterial pressure > 65mmHg) before initiation of study medication
- More than 5 units of RBC necessary to maintain a haemoglobin level >8mg/dl at the end of surgery
- Prior cardiac surgery within the past 6 months
See the full eligibility criteria
Who can join
- Male or female patients ≥ 18 years old
- Written informed consent from patient
- Patients are in sinus rhythm
- Oral Betablocker in the patients long-term medication
- One of the following cardiac surgical procedures which is planned on cardiopulmonary bypass (CPB): a. Single valve surgery b. Single or multiple CABG procedures c. Single valve surgery in combination with one or multiple coronary artery bypass grafts (CABGs) d. Multiple valve surgery in combination with or without CABG e. Single or multiple valve surgery in combination with ascending aorta procedure with or without additional CABG f. Re-surgery of aortic valve, mitral valve, aortic arch or ascending aorta with or without CABG
- Cardiac surgery is performed electively
What rules you out
- Bodyweight > 101kg and/or BMI ≥ 40
- Requiring inotropic, vasopressor or requiring ventilatory support at time of screening
- Circulatory shock requiring mechanical circulatory support before initiation of study medication
- Distributive shock (cardiac index>2.2 L/min with norepinephrine dose > 0.3 µg/kg/min to reach mean arterial pressure > 65mmHg) before initiation of study medication
- More than 5 units of RBC necessary to maintain a haemoglobin level >8mg/dl at the end of surgery
- Prior cardiac surgery within the past 6 months
- History of heart transplantation or planned heart transplantation
- Any other disease or condition that is likely to interfere with the evaluation of the study drug, outcome assessment or satisfactory conduct of the study: a. Active infective endocarditis b. Stroke or transient ischemic attack (TIA) within the last 6 months c. Concomitant disease with a life expectancy of less than 6 months d. Cardiopulmonary resuscitation within the last 4 weeks e. Patients requiring renal replacement therapy
- Active infection on current systemic antibiotics and/ or temperature greater than 38°C at time of screening and before start of surgery
- Haemoglobin < 5 mmol/l (< 8.06 g/dl)
- Any systemic anti-cancer therapy within past 3 months
- Cardiac surgery is planned as minimally invasive procedure (e.g., without thoracotomy or with lateral incision, minimal thoracotomy) or planned as off-pump surgery
- Patients with known hypersensitivity to any constituent of the IMP
- General exclusion criteria: a. Pregnant (in women of childbearing potential a urine or blood pregnancy test has to be performed) or breast-feeding women. Women with childbearing potential (defined as within two years of their last menstruation) not willing to practice appropriate contraceptive measures (e.g., implanon, injections, oral contraceptives, intrauterine devices, partner with vasectomy, abstinence) while participating in the trial b. Participation in any interventional clinical trial within the last one-month prior randomization in this clinicaltrial (screening failures can be rescreened, if appropriate) c. Alcohol, drug, or medication abuse d. Employee at the study site, spouse/partner or relative of any study staff (e.g., investigator, subinvestigators, or study nurse) or relationship to the sponsor
- Planned maze procedure, radiofrequency ablation, pulmonary vein ablation, resection of the atrial appendix or atrial resections during the surgery
- Sinus bradycardia (resting heart rate < 50/min) at screening and before start of IMP treatment
- Second- or third-degree atrioventricular block at screening and before start of IMP treatment
- Clinical hypothyroidism or hyperthyroidism at screening
- History of ventricular arrhythmia
- Permanent atrial fibrillation or atrial fibrillation at time of screening and IMP administration
- Emergency cardiac surgery
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.